NCT03334708

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 700 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Conditions

• Pancreatic Cancer
• Pancreatic Diseases
• Pancreatitis
• Pancreatic Cyst

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Blood Draw	If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria: Patients and controls weighing 50kg or more * For draw amounts up to 50mL, there is no required hemoglobin threshold. * For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period. Patients and controls weighing \< 50kg * For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time.
DIAGNOSTIC_TEST	Tumor Tissue Collection	Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
DIAGNOSTIC_TEST	Cyst Fluid	Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

Timeline

• Start date: 2017-10-30
• Primary completion: 2026-10-30
• Completion: 2026-10-30
• First posted: 2017-11-07
• Last updated: 2025-12-02

Locations

13 sites across 2 countries: United States, Israel